PolyTherics expands big pharma collaboration; Marijuana chewing gum hits market trials;

> In its first public presentation, Civitas Therapeutics' CVT-301, a breath-actuated formulation of levodopa (L-dopa) in Phase IIa development for the treatment of Parkinson's disease, reached therapeutic dose levels within 5 minutes. Phase IIa results are expected early next year. Press release

> PolyTherics has expanded its collaboration with an undisclosed top-5 pharma company to develop delivery systems for a number of its partner's therapeutic proteins. PolyTherics' PolyPEG polymer extends the half-life of proteins in the body. Press release

> New Haven Pharmaceuticals has raised $6.5 million of a hoped-for $7.7 million round of funding to support its development of a once-daily anti-platelet drug to prevent stroke and cardiovascular events. Article

> Catalent presented a range of posters on drug delivery at the 2012 AAPS Annual Meeting and Exposition. Article

> Taiwan Liposome filed an IPO submission with GreTai Securities Market. Article

> According to a review in the Journal of Aerosol Medicine and Pulmonary Drug Delivery, pulmonary vaccine delivery makes an attractive alternative to traditional injections. Press release | Abstract

> iCo Therapeutics has presented preclinical data on its oral Amphotericin B delivery system at the 2012 AAPS Annual Meeting and Exposition, and has also received a new patent in Singapore. Press release

> Arrowhead Research has received a U.S. patent for a new formulation of its Dynamic Polyconjugate (DPC) siRNA delivery platform. Press release

> A dissolving oral strip has been developed to deliver local anesthetic for burns caused by eating or drinking stuff that's too hot--so perfect when the cheese on that pizza just catches the roof of your mouth… Press release

And Finally… Chewable weed? Medical Marijuana and CanChew Biotechnologies have started a market trial of the CanChew CBD chewing gum product line for patients with pain from MS muscular spasticity, cancer, neuropathic conditions and arthritis, as well as psychological and mood disorders. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.